2017
DOI: 10.1080/1744666x.2017.1400380
|View full text |Cite
|
Sign up to set email alerts
|

The role of blood and CSF biomarkers in the evaluation of new treatments against multiple sclerosis

Abstract: Multiple sclerosis (MS) is an immune-mediated chronic neurodegenerative disease of the central nervous system (CNS). Therapeutic interventions with immunomodulatory agents reduce disease activity and disability development, which are monitored clinically and by magnetic resonance imaging (MRI). However, these measures largely lack information on the impact from these therapies on inflammation, demyelination and axonal injury, the essential pathophysiological features of MS. Several biomarkers for inflammation … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
17
0
1

Year Published

2018
2018
2022
2022

Publication Types

Select...
10

Relationship

3
7

Authors

Journals

citations
Cited by 22 publications
(19 citation statements)
references
References 113 publications
1
17
0
1
Order By: Relevance
“…The presence of these metabolic markers not only in CSF but also in an easily accessible body fluid like blood suggests a potential role of these molecules as biomarkers for disease activity and progression in course of MS. Thus, as was the case for other biomarkers [40], further studies are warranted to validate the use of these promising molecules, in particular (i) on patients presenting clinically isolated syndromes and on healthy controls to evaluate the capability to guide an early diagnosis of MS, and (ii) during immunomodulating treatment for the monitoring of disease activity and progression.…”
Section: Discussionmentioning
confidence: 99%
“…The presence of these metabolic markers not only in CSF but also in an easily accessible body fluid like blood suggests a potential role of these molecules as biomarkers for disease activity and progression in course of MS. Thus, as was the case for other biomarkers [40], further studies are warranted to validate the use of these promising molecules, in particular (i) on patients presenting clinically isolated syndromes and on healthy controls to evaluate the capability to guide an early diagnosis of MS, and (ii) during immunomodulating treatment for the monitoring of disease activity and progression.…”
Section: Discussionmentioning
confidence: 99%
“…Neurofilament light chain (NfL) is a component of the neuronal cytoskeleton and is released into the cerebrospinal fluid (CSF) and blood after neuronal-axonal injury (10,11). Serum NfL (sNfL) measured via ultra-sensitive single-molecule arrays (SIMOA) has been observed to be increased in multiple neurological diseases-including neurodegenerative disorders, trauma, and multiple sclerosis (MS)-and strongly correlates with CSF NfL (12)(13)(14)(15).…”
Section: Introductionmentioning
confidence: 99%
“…Multiple sclerosis is believed to be driven by systemic immune activation of autoimmunity against CNS components (4,5), where encephalitogenic cells accumulate in the target organ (6,7). Due to the proximity to the CNS, cerebrospinal fluid (CSF) has been the primary object of biomarker exploration (8,9). Immunoglobulin G (IgG) index and detection of oligoclonal bands are currently used to support diagnosis (10).…”
mentioning
confidence: 99%